CYTK Cytokinetics Incorporated

+0.77  (+6%)
Previous Close 12.49
Open 12.51
Price To Book -165.75
Market Cap 778,082,134
Shares 58,678,894
Volume 462,456
Short Ratio
Av. Daily Volume 451,559

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data presented at AAN, May 5, 2019, failed to meet primary endpoint.
Reldesemtiv (CK-2127107) - FORTITUDE-ALS
Amyotrophic lateral sclerosis (ALS)
Phase 1b interim analysis noted lack of efficacy.
Limited mobility
Phase 3 interim analysis 1H 2020.
Omecamtiv mecarbil GALACTIC-HF
Acute heart failure
Phase 3 data released November 21, 2017 - primary endpoint not met.
Tirasemtiv - VITALITY
Amyotrophic lateral sclerosis (ALS)
Phase 2 data did not meet endpoints - October 5, 2018.
Reldesemtiv (CK-2127107)
Chronic obstructive pulmonary disease (COPD)
Second Phase 3 trial initiation announced February 21, 2019.
Omecamtiv mecarbil METEORIC-HF
Acute heart failure
Phase 1 data due at HFSA September 13-16, 2019.
Healthy volunteers (hypertrophic cardiomyopathy (HCM))
Phase 1 trial initiation announced February 20, 2019.
AMG 594
Healthy volunteers

Latest News

  1. Edited Transcript of CYTK earnings conference call or presentation 8-Aug-19 8:30pm GMT
  2. Cytokinetics Inc (CYTK) Q2 2019 Earnings Call Transcript
  3. Cytokinetics (CYTK) Reports Q2 Loss, Tops Revenue Estimates
  4. Cytokinetics Reports Second Quarter 2019 Financial Results
  5. Analysts Estimate Cytokinetics (CYTK) to Report a Decline in Earnings: What to Look Out for
  6. Cytokinetics Announces Preclinical Data for CK-3773274 Presented at the American Heart Association’s Basic Cardiovascular Sciences Scientific Sessions
  7. Health Care Digest: Kilroy's Oyster Point mystery, helping researchers ditch spreadsheets — and more
  8. Does Cytokinetics, Incorporated (NASDAQ:CYTK) Have A Volatile Share Price?
  9. First big lease lands at Kilroy's huge Oyster Point project
  10. Cytokinetics to Announce Second Quarter Results on August 8, 2019
  11. Cytokinetics Announces Publication of Preclinical Data Demonstrating Fast Skeletal Muscle Troponin Activator Improves Muscle Energetics
  12. Cytokinetics Granted European Orphan Designation for Reldesemtiv for the Treatment of Spinal Muscular Atrophy
  13. Cytokinetics Announces Preclinical Data Relating to CK-3773274 to be Presented at the American Heart Association’s Basic Cardiovascular Sciences Scientific Sessions
  14. Cytokinetics Announces Completion of Enrollment in GALACTIC-HF, Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure
  15. Cytokinetics Announces Preclinical Data For Reldesemtiv Presented at the 2019 Annual Cure SMA Conference
  16. Did Hedge Funds Drop The Ball On Cytokinetics, Inc. (CYTK) ?
  17. Cytokinetics Announces Preclinical Data for Reldesemtiv to be Presented at the 2019 Annual Cure SMA Conference
  18. Could The Cytokinetics, Incorporated (NASDAQ:CYTK) Ownership Structure Tell Us Something Useful?
  19. Cytokinetics to Present at the JMP Securities Life Sciences Conference